Claims
- 1. A method of inhibiting thrombin in a mammal comprising administering to a mammal in need thereof an effective amount of a thrombin inhibiting compound of formula I (or a pharmaceutically acceptable salt thereof) ##STR700## wherein A is O or S;
- A.sup.2 is para-phenylene which divalent radical may bear a hydroxymethyl, benzyloxymethyl, (1-3C)alkyl, (1-2C)alkoxy, hydroxy or halo substituent;
- A.sup.3 is para-phenylene which divalent radical may bear one or two substituents independently selected from dimethylamino, (1-4C)alkyl, halo, trifluoromethyl, (1-2C)alkoxy, hydroxy, cyano, aminomethyl, nitro, --NHCH.sub.2 R.sup.f, --NHC(O)R.sup.f or --NHS(O).sub.2 R.sup.g in which R.sup.f is hydrogen or (1-2C)alkyl and R.sup.g is (1-2C)alkyl or phenyl;
- R.sup.1 denotes 0, 1 or 2 substituents on the benz-ring independently selected from halo, methyl, ethyl, hydroxy, methoxy, carbamoyl, aminomethyl and hydroxymethyl;
- X.sup.1 is O, S, methylene, carbonyl or ethene-1,1-diyl;
- (a) X.sup.2 is imino, a direct bond, methylene, O or S; j is 0; k is 0; m is 5, 1, 2, 3 or 4; provided that when m is 1, then X.sup.2 is a direct bond; and Ra and Rb are independently hydrogen or (1-3C)alkyl or the group NRaRb is 1-imidazolyl, 1-pyrazolyl, N-(1,2,4-triazolyl), neopentylamino, (cyclohexylmethyl) amino, benzylamino, (3-pyridylmethyl) amino, (2, 3-dihydroxypropyl) amino, (1-iminoethyl) amino, 2-(hydroxymethyl)-1-pyrrolidinyl, 2-(methoxymethyl)-1-pyrrolidinyl, pyrrolidino, piperidino, 2-methyl-1-piperidinyl, morpholino or hexamethyleneimino; or
- (b) X.sup.2 is imino, O or S; j is 1; k is 1; m is 1; R.sup.2 is hydroxy; and R.sup.a and R.sup.b are independently hydrogen or (1-3C)alkyl or the group NRaRb is pyrrolidino, piperidino, morpholino or hexamethyleneimino; or
- (c) X.sup.2 is imino, O or S; j is 1; k is 1; m is 0; R.sup.2 is methyl, carboxy, hydroxymethyl or methoxycarbonyl; and R.sup.a and R.sup.b are independently hydrogen or (1-3C)alkyl; or
- (d) x.sup.2 is imino, O or S; j is 0, 1, 2 or 3; k is 1; m is 0 or 1; provided that j and m are not both 0; R.sup.2 and R.sup.a together form a diradical --(CH.sub.2).sub.n -- in which n is 2, 3 or 4 and the sum of m and n is 3 or 4; and R.sup.b is hydrogen or (1-3C)alkyl; or
- (e) X.sup.2 is --NH--C(O)--; j is 0; k is 0; m is 1; and R.sup.a and R.sup.b are independently hydrogen or (1-3C)alkyl or the group NR.sup.a R.sup.b is 1,1-dioxothiomorpholin-4-yl, pyrrolidino, piperidino, morpholino or hexamethyleneimino; and
- (1) X.sup.3 is a direct bond, methylene, imino, O or S; q is 0, 1 or 2; and r is 0 or 1; provided that q and r are not both zero, and provided that when q is 1 and r is 0, then X.sup.3 is a direct bond; each R.sup.3 is hydrogen or the two R.sup.3 groups together form a divalent radical --(CH.sub.2).sub.s -- in which s is 3 or 4; or q and r are each 1 and the group --(CHR.sup.3 --CHR.sup.3)-- is propane-2,2-diyl; and R.sup.c and R.sup.d are independently hydrogen or (1-4C)alkyl or the group NRCRd is 1-pyrazolyl, 2-(hydroxymethyl)-1-pyrrolidinyl, 2-(methoxymethyl)-1-pyrrolidinyl, pyrrolidino, piperidino, morpholino, hexamethyleneimino, 1-imidazolyl or 4,5-dihydro-1-imidazolyl; or
- (2) X.sup.3 is imino, O or S; q is 0; r is 1; one R.sup.3 group is (1-5C)alkyl and the other R.sup.3 group is independently hydrogen or (1-5C)alkyl; and R.sup.c and R.sup.d are independently hydrogen or (1-3C)alkyl or the group NR.sup.c R.sup.d is pyrrolidino, piperidino, morpholino or hexamethyleneimino; or
- (3) X.sup.3 is imino, O or S; q is 0, 1 or 2; r is 1; one R.sup.3 group is hydrogen and the other R.sup.3 group together with the group R.sup.c forms a divalent radical --(CH.sub.2).sub.t -- in which t is 2, 3 or 4 such that the resulting ring is a pyrrolidine or piperidine; and R.sup.d is hydrogen or (1-3C)alkyl; or
- (4) X.sup.3 is --N(Rh)--; q is 0; r is 1; the R.sup.3 group on the carbon bonded to X.sup.3 and the group R.sup.h together form a diradical --(CH.sub.2).sub.3 --; the other R.sup.3 group is hydrogen; and Rc and R.sup.d are independently (1-3C)alkyl or the group NR.sup.c R.sup.d is pyrrolidino, piperidino, morpholino or hexamethyleneimino; or
- (5) X.sup.3 is ethene-1,2-diyl or ethyne-1,2-diyl; q is 1; r is 0; and Rc and Rd are independently (1-3C)alkyl or the group NR.sup.c R.sup.d is pyrrolidino, piperidino, morpholino or hexamethyleneimino.
- 2. The method of claim 1 wherein said compound is a compound of formula Ia ##STR701## wherein A is S;
- D is CH or CR.sup.j in which R.sup.j is methyl, hydroxy or methoxy;
- E is CH or CR.sup.e in which R.sup.e is (1-3C)alkyl, (1-2C)alkoxy or halo;
- R.sup.5 is hydrogen, halo, methyl, hydroxy or methoxy;
- R.sup.6 is hydrogen, hydroxy or methoxy;
- X.sup.1 is O, S, methylene, carbonyl or ethene-1,1-diyl;
- x.sup.2a is methylene or O; and R.sup.a and R.sup.b are independently hydrogen or (1-3C)alkyl or the group NR.sup.a R.sup.b is pyrrolidino or piperidino;
- x.sup.3 a is methylene, imino, O, or S; and each R.sup.3 is hydrogen or the two R.sup.3 groups together form a divalent radical --(CH.sub.2).sub.s -- in which s is 3 or 4; and R.sup.c and R.sup.d are independently (1-3C)alkyl or the group NR.sup.c R.sup.d is pyrrolidino, piperidino, morpholino or hexamethyleneimino or 1-imidazolyl.
- 3. The method of claim 2 wherein D is CH; and E is CH or CR.sup.e in which R.sup.e is (1-3C)alkyl or halo.
- 4. The method of claim 2 wherein A is S; D is CH; E is CRe in which Re is methoxy; R.sup.5 is hydrogen; R.sup.6 is hydroxy; X.sup.1 is methylene; X.sup.2a is O; and the group NR.sup.a R.sup.b is pyrrolidino; X.sup.3a is O; and the two R.sup.3 groups together form a divalent radical --(CH.sub.2).sub.s -- in which s is 4 and which forms a trans-1,2-cyclohexanediyl group; and R.sup.c and R.sup.d are each methyl or the group NR.sup.c R.sup.d is pyrrolidino.
- 5. The method of claim 1 wherein said compound is a compound of formula Ib ##STR702## wherein A is S;
- G is CH or CR.sup.k in which R.sup.k is methyl, hydroxy or methoxy;
- M is CH or CR.sup.m in which R.sup.m is (1-3C)alkyl, (1-2C)alkoxy or halo;
- R.sup.5 is hydrogen, halo, methyl, hydroxy or methoxy;
- R.sup.6 is hydrogen, hydroxy or methoxy;
- X.sup.1 is O, S, methylene, carbonyl or ethene-1,1-diyl;
- X.sup.2b is a direct bond or O; R.sup.a and R.sup.b are independently hydrogen or (1-3C)alkyl or the group NR.sup.a R.sup.b is pyrrolidino or piperidino; and
- R.sup.c and R.sup.d are independently (1-3C)alkyl or the group NRCRd is 2-(hydroxymethyl)-1-pyrrolidinyl, 2-(methoxymethyl)-1-pyrrolidinyl, pyrrolidino, piperidino or morpholino.
- 6. The method of claim 5 wherein A is S; G is CH; M is CH or CR.sup.m in which R.sup.m is methyl, methoxy, chloro or bromo; R.sup.5 is hydrogen; R.sup.6 is hydroxy; X.sup.1 is methylene; X.sup.2b is a direct bond or O; the group NR.sup.a R.sup.b is pyrrolidino; and R.sup.c and R.sup.d are each methyl or the group NR.sup.c R.sup.d is 2-(hydroxymethyl)-1-pyrrolidinyl, 2-(methoxymethyl)-1-pyrrolidinyl, pyrrolidino or morpholino.
- 7. The method as claimed in claim 1 wherein said compound is one in which X.sup.1 is methylene, s (when present) is 4, and A is S.
- 8. The method as claimed in claim 1 wherein said compound is a compound of formula I in which R.sup.1 denotes a hydroxy substituent at the 6-position of the benzo[b]thiophene.
- 9. A novel compound of formula I (or a pharmaceutically acceptable salt thereof) ##STR703## wherein A is O or S;
- A.sup.2 is para-phenylene which divalent radical may bear a hydroxymethyl, benzyloxymethyl, (1-3C)alkyl, (1-2C)alkoxy, hydroxy or halo substituent;
- A.sup.3 is para-phenylene which divalent radical may bear one or two substituents independently selected from dimethylamino, (1-4C)alkyl, halo, trifluoromethyl, (1-2C)alkoxy, hydroxy, cyano, aminomethyl, nitro, --NHCH.sub.2 R.sup.f, --NHC(O)R.sup.f or --NHS(O).sub.2 R.sup.g in which R.sup.f is hydrogen or (1-2C)alkyl and R.sup.g is (1-2C)alkyl or phenyl;
- R.sup.1 denotes 0, 1 or 2 substituents on the benz-ring independently selected from halo, methyl, ethyl, hydroxy, methoxy, carbamoyl, aminomethyl and hydroxymethyl;
- X.sup.1 is O, S, methylene, carbonyl or ethene-1,1-diyl;
- (a) X.sup.2 is imino, a direct bond, methylene, O or S; j is 0; k is 0; m is 5, 1, 2, 3 or 4; provided that when m is 1, then X.sup.2 is a direct bond; and R.sup.a and R.sup.b are independently hydrogen or (1-3C)alkyl or the group NR.sup.a R.sup.b is 1-imidazolyl, 1-pyrazolyl, N-(1,2,4-triazolyl), neopentylamino, (cyclohexylmethyl) amino, benzylamino, (3-pyridylmethyl) amino, (2,3-dihydroxypropyl) amino, (1-iminoethyl) amino, 2-(hydroxymethyl)-1-pyrrolidinyl, 2-(methoxymethyl)-1-pyrrolidinyl, pyrrolidino, piperidino, 2-methyl-1-piperidinyl, morpholino or hexamethyleneimino; or
- (b) X.sup.2 is imino, O or S; j is 1; k is 1; m is 1; R.sup.2 is hydroxy; and R.sup.a and R.sup.b are independently hydrogen or (1-3C)alkyl or the group NR.sup.a R.sup.b is pyrrolidino, piperidino, morpholino or hexamethyleneimino; or
- (c) X.sup.2 is imino, O or S; j is 1; k is 1; m is 0; R.sup.2 is methyl, carboxy, hydroxymethyl or methoxycarbonyl; and R.sup.a and R.sup.b are independently hydrogen or (1-3C)alkyl; or
- (d) X.sup.2 is imino, O or S; j is 0, 1, 2 or 3; k is 1; m is 0 or 1; provided that j and m are not both 0; R.sup.2 and R.sup.a together form a diradical --(CH.sub.2).sub.n -- in which n is 2, 3 or 4 and the sum of m and n is 3 or 4; and Rb is hydrogen or (1-3C)alkyl; or
- (e) X.sup.2 is --NH--C(O)--; j is 0; k is 0; m is 1; and R.sup.a and R.sup.b are independently hydrogen or (1-3C)alkyl or the group NR.sup.a R.sup.b is 1,1-dioxothiomorpholin-4-yl, pyrrolidino, piperidino, morpholino or hexamethyleneimino; and
- (1) X.sup.3 is a direct bond, methylene, imino, O or S; q is 0, 1 or 2; and r is 0 or 1; provided that q and r are not both zero, and provided that when q is 1 and r is 0, then X.sup.3 is a direct bond; each R.sup.3 is hydrogen or the two R.sup.3 groups together form a divalent radical --(CH.sub.2).sub.s -- in which s is 3 or 4; or q and r are each 1 and the group --(CHR.sup.3 --CHR.sup.3)-- is propane-2,2-diyl; and R.sup.c and R.sup.d are independently hydrogen or (1-4C)alkyl or the group NR.sup.c R.sup.d is 1-pyrazolyl, 2-(hydroxymethyl)-1-pyrrolidinyl, 2-(methoxymethyl)-1-pyrrolidinyl, pyrrolidino, piperidino, morpholino, hexamethyleneimino, 1-imidazolyl or 4,5-dihydro-1-imidazolyl; or
- (2) X.sup.3 is imino, O or S; q is 0; r is 1; one R.sup.3 group is (1-5C)alkyl and the other R.sup.3 group is independently hydrogen or (1-5C)alkyl; and R.sup.c and R.sup.d are independently hydrogen or (1-3C)alkyl or the group NR.sup.c R.sup.d is pyrrolidino, piperidino, morpholino or hexamethyleneimino; or
- (3) X.sup.3 is imino, O or S; q is 0, 1 or 2; r is 1; one R.sup.3 group is hydrogen and the other R.sup.3 group together with the group RC forms a divalent radical --(CH.sub.2).sub.t -- in which t is 2, 3 or 4 such that the resulting ring is a pyrrolidine or piperidine; and Rd is hydrogen or (1-3C)alkyl; or
- (4) X.sup.3 is --N(R.sup.h)--; q is 0; r is 1; the R.sup.3 group on the carbon bonded to X.sup.3 and the group R.sup.h together form a diradical --(CH.sub.2).sub.3 --; the other R.sup.3 group is hydrogen; and R.sup.c and R.sup.d are independently (1-3C)alkyl or the group NR.sup.c R.sup.d is pyrrolidino, piperidino, morpholino or hexamethyleneimino; or
- (5) X.sup.3 is ethene-1,2-diyl or ethyne-1,2-diyl; q is 1; r is 0; and R.sup.c and R.sup.d are independently (1-3C)alkyl or the group NR.sup.c R.sup.d is pyrrolidino, piperidino, morpholino or hexamethyleneimino;
- provided that the compound is not one in which A is S; A.sup.2 is para-phenylene; A.sup.3 is para-phenylene; R.sup.1 denotes zero substituents on the benz-ring or R.sup.1 denotes a hydroxy or methoxy substituent at the 6-position of the benzo[b]thiophene ring; X.sup.1 is carbonyl; X.sup.2 is O; j and k are both 0, the group --(CH.sub.2).sub.m -- is ethylene or propylene; R.sup.a and R.sup.b are independently (1-3C)alkyl or the group NR.sup.a R.sup.b is pyrrolidino, piperidino, morpholino or hexamethyleneimino; X.sup.3 is 0; the group --(CH.sub.2).sub.q -- (CHR.sup.3 --CHR.sup.3).sub.r -- is ethylene or propylene; and R.sup.c and R.sup.d are independently (1-3C)alkyl or the group NR.sup.c R.sup.d is pyrrolidino, piperidino, morpholino or hexamethyleneimino.
- 10. The compound (or pharmaceutically acceptable salt thereof) as claimed in claim 9 which is a compound of formula Ia ##STR704## wherein A is S;
- D is CH or CR.sup.j in which R.sup.j is methyl, hydroxy or methoxy;
- E is CH or CR.sup.e in which R.sup.e is (1-3C)alkyl, (1-2C)alkoxy or halo;
- R.sup.5 is hydrogen, halo, methyl, hydroxy or methoxy;
- R.sup.6 is hydrogen, hydroxy or methoxy;
- X.sup.1 is O, S, methylene, carbonyl or ethene-1,1-diyl;
- X.sup.2a is methylene or O; and R.sup.a and R.sup.b are independently hydrogen or (1-3C)alkyl or the group NR.sup.a R.sup.b is pyrrolidino or piperidino;
- X.sup.3a is methylene, imino, O, or S; and each R.sup.3 is hydrogen or the two R.sup.3 groups together form a divalent radical --(CH.sub.2).sub.s -- in which s is 3 or 4; and R.sup.c and R.sup.d are independently (1-3C)alkyl or the group NR.sup.c R.sup.d is pyrrolidino, piperidino, morpholino or hexamethyleneimino or 1-imidazolyl;
- provided that the compound is not one in which A is S; D is CH; E is CH; R.sup.5 is hydrogen, R.sup.6 is hydrogen, hydroxy or methoxy; X.sup.1 is carbonyl; x.sup.2 a is O; Ra and Rb are independently (1-3C)alkyl or the group NR.sup.a R.sup.b is pyrrolidino or piperidino; X.sup.3a is O; each R.sup.3 is hydrogen; and R.sup.c and R.sup.d are independently (1-3C)alkyl or the group NR.sup.a R.sup.d is pyrrolidino, piperidino, morpholino or hexamethylenemino.
- 11. The compound (or pharmaceutically acceptable salt thereof) of claim 10 wherein D is CH; and E is CH or CR.sup.e in which R.sup.e is (1-3C)alkyl or halo.
- 12. The compound (or pharmaceutically acceptable salt thereof) of claim 10 wherein A is S; D is CH; E is CR.sup.e in which R.sup.e is methoxy; R.sup.5 is hydrogen; R.sup.6 is hydroxy; X.sup.1 is methylene; X.sup.2a is O; and the group NR.sup.a R.sup.b is pyrrolidino; X.sup.3a is O; and the two R.sup.3 groups together form a divalent radical --(CH.sub.2).sub.s -- in which s is 4 and which forms a trans-1,2-cyclohexanediyl group; and R.sup.c and R.sup.d are each methyl or the group NR.sup.c R.sup.d is pyrrolidino.
- 13. The compound (or pharmaceutically acceptable salt thereof) as claimed in claim 9 which is a compound of formula Ib ##STR705## wherein A is S;
- G is CH or CR.sup.k in which R.sup.k is methyl, hydroxy or methoxy;
- M is CH or CR.sup.m in which R.sup.m is (1-3C)alkyl, (1-2C)alkoxy or halo;
- R.sup.5 is hydrogen, halo, methyl, hydroxy or methoxy;
- R.sup.6 is hydrogen, hydroxy or methoxy;
- X.sup.1 is O, S, methylene, carbonyl or ethene-1,1-diyl;
- X.sup.2b is a direct bond or O; R.sup.a and R.sup.b are independently hydrogen or (1-3C)alkyl or the group NR.sup.a R.sup.b is pyrrolidino or piperidino; and
- R.sup.c and R.sup.d are independently (1-3C)alkyl or the group NR.sup.c R.sup.d is 2-(hydroxymethyl)-1-pyrrolidinyl, 2-(methoxymethyl)-1-pyrrolidinyl, pyrrolidino, piperidino or morpholino.
- 14. The compound (or pharmaceutically acceptable salt thereof) of claim 13 wherein A is S; G is CH; M is CH or CR.sup.m in which R.sup.m is methyl, methoxy, chloro or bromo; R.sup.5 is hydrogen; R.sup.6 is hydroxy; X.sup.1 is methylene; X.sup.2b is a direct bond or O; the group NR.sup.a R.sup.b is pyrrolidino; and R.sup.c and R.sup.d are each methyl or the group NR.sup.c R.sup.d is 2-(hydroxymethyl)-1-pyrrolidinyl, 2-(methoxymethyl)-1-pyrrolidinyl, pyrrolidino or morpholino.
- 15. The compound (or pharmaceutically acceptable salt thereof) as claimed in claim 9 wherein X.sup.1 is methylene, s (when present) is 4, and A is S.
- 16. The compound (or pharmaceutically acceptable salt thereof) as claimed in claim 15 wherein said compound is a compound of formula I in which R.sup.1 denotes a hydroxy substituent at the 6-position of the benzo[b]thiophene.
- 17. An acid addition salt of a novel compound of formula I as claimed in claim 9 made with an acid which affords a pharmaceutically acceptable anion.
- 18. A pharmaceutical formulation comprising in association with a pharmaceutically acceptable carrier, diluent or excipient, a novel compound of formula I (or a pharmaceutically acceptable salt thereof) as claimed in claim 9.
- 19. An alcohol of formula II ##STR706## wherein the values of A, A.sup.2, A.sup.3, R.sup.1, R.sup.2, R.sup.3, R.sup.a, R.sup.b, R.sup.c, R.sup.d, X.sup.1, X.sup.2, X.sup.3, j, k, m, q, and r are as defined in claim 1.
- 20. The method of claim 1 wherein said compound is 6-hydroxy-3-[3-methoxy-4-[(1-pyrrolidinyl)methyl]benzyl]-2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]benzo[b]thiophene.
- 21. The novel compound (or pharmaceutically acceptable salt thereof) of claim 9 wherein said compound is 6-hydroxy-3-[3-methoxy-4-[(1-pyrrolidinyl)methyl]benzyl]-2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]benzo[b]thiophene.
Parent Case Info
This application is a continuation-in-part of U.S. national application Ser. No. 08/836,680, filed on Apr. 30, 1996, now abandoned the national stage application of international application PCT/US96/17995, filed Oct. 30, 1996, which international application claims priority from U.S. provisional application Ser. No. 60/007,120, filed Oct. 31, 1995, and U.S. provisional application Ser. No. 60/028,252, filed Oct. 9, 1996.
US Referenced Citations (9)
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9510513 |
Apr 1995 |
WOX |
Non-Patent Literature Citations (2)
Entry |
Jones, C., et al., "Synthesis and Antiestrogenic Activity of [3,4-Dihydro-2-(4-methoxyphenyl) -1-napthalenyl] [4-[2-(1-pyrrolidinyl) ethoxy] phenyl] methanone, Methanesulfonic Acid Salt", J. Med. Chem., 22(8), 962-966, 1979. |
Jones, C., et al., "Antiestrogens. 2. Structure-Activity Studies in a Series of 3-Aroyl-2-arylbenzo [b] thiophene Derivatives Leading to [6-Hydroxy-2-(4-hydroxyphenyl) benzo [b] thien-3-yl] [4-[2-(1-piperidinyl) ethoxy] phenyl] methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogencity," J. Med. Chem., 27 (8), 1057-1066, 1984. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
836680 |
|
|